Switzerland’s Eighth Cannabis Pilot Tests Home Delivery

Switzerland is preparing to test whether letting adults order cannabis to their front door can pull consumers away from the illicit market. The country’s Federal Office of Public Health has authorised an eighth adult-use pilot trial — the first to include home delivery — extending a regulated-access experiment that other governments weighing legalisation are watching closely.

The trial, called CanLeg, will run in the northeastern canton of St. Gallen and was presented on June 16, 2026 by the non-profit Swiss Cannabis Research association. It is a randomised controlled trial planned to run from 2026 to 2031, with a total sample of up to 5,000 people, according to the regulator’s project profile. Participants are split into three randomly assigned groups: two will be able to buy legal cannabis — through a pharmacy or by delivery — while the third serves as a control group with no access. That leaves roughly 3,300 adults able to purchase legally, Swiss public broadcaster SWI swissinfo.ch reported.

CanLeg is run by economists at the KOF Swiss Economic Institute at ETH Zurich and the University of Zurich’s economics department. It is the second project for Swiss Cannabis Research, which also runs Cannabis Research Zürich, the country’s largest pilot to date. Legal sales will operate through pharmacies and specialty stores in five St. Gallen communes — Wil, Buchs, Rorschach, Sargans and Rapperswil-Jona — alongside the new mail-order channel.

Why the delivery channel matters

The novelty is not convenience for its own sake. By randomly assigning buyers to a pharmacy counter or a delivery service, researchers can isolate whether the channel of access — not just the fact that it is legal — shapes how people consume. The trial’s core question is whether that access changes how much they use and whether they stop buying from street dealers. CanLeg runs in two stages: a short opening phase measuring what participants will pay for different products and how they rate quality, followed by a study of up to four years tracking how the point of access affects consumption, health and displacement of the black market.

That displacement question sits at the centre of Switzerland’s whole experiment — the working theory that legal, quality-controlled access can shrink the illicit trade without pushing up consumption. The regulator classifies CanLeg as a commercial-market model — one of several structures being tested across the eight authorised trials, which also include non-profit, state-run and mixed operations. Products on offer — flower, hashish, THC oils, vapes and edibles — must come from Swiss producers approved by the regulator and tested for potency and contaminants, a domestic-sourcing rule that has already drawn established operators into the pilot system with an eye on a larger national market.

A bounded experiment, not legalisation

For all the expansion, recreational cannabis remains illegal in Switzerland. The trials exist only because of a 2021 amendment to the Narcotics Act that opened a narrow, time-limited legal window for scientific pilots. The window is tightly drawn: no trial may enrol more than 5,000 people or run longer than five years, each needs both regulator authorisation and ethics-committee approval, advertising is banned outright, and the whole legal exception expires in 2031.

That distinction — a research carve-out rather than a legal market — is easy to lose in the headlines. The first trial, Basel-Stadt’s WeedCare, opened in pharmacies in January 2023. By mid-2025, about 10,400 adults were taking part across the seven pilots then running — fewer than 5% of the roughly 220,000 Swiss who report using cannabis in a typical month. The trials are deliberately small, closely monitored, and built to produce evidence rather than a market.

What Switzerland is building toward

The pilots feed a larger decision. Swiss authorities are drafting a Cannabis Products Act that would regulate adult use nationwide; a public consultation on the bill closed in December 2025, and parliament has yet to debate it. The online-sales channel CanLeg is now testing is itself contested — the right-wing Swiss People’s Party used the consultation to attack constant cannabis availability through the internet as reckless — which makes real-world data on delivery all the more useful to the coming fight.

Whether the law passes, and in what shape, will turn partly on what the trials show — reinforcing a lesson emerging across Europe that how a market is designed matters as much as whether it opens at all. CanLeg’s contribution is a narrow but useful one: evidence on whether a legal delivery channel — the kind a future commercial market would almost certainly include — actually moves consumers out of the shadow economy. Regulators elsewhere, from Germany to the wider region, are running their own experiments and will be reading St. Gallen’s data alongside their own.